Glenmark, a multinational pharmaceutical company, has partnered with AI data-driven supply chain management platform 7bridges.
Initially focusing on their European business, where they have operations in 15 markets, the supply chain and logistics function is a big focus area for this cost
reduction.
The partnership with 7bridges will allow Glenmark to baseline their supply chain data giving them visibility of data, cost and service performance across their
network of logistics service providers.
This exercise will identify areas where invoices from their logistics service providers are being incorrectly or overcharged. With automatic dispute raising,
savings will be quickly achieved. The platform will then enable Glenmark to benchmark their data, so they can compare the performance and cost of their LSPs to the
wider industry.
With Glenmark's global vision to emerge as a leading integrated research-based global pharmaceutical company, this investment in their supply chain will be integral
to achieving this.
The next step in the partnership will be to run simulations to optimise road freight services and 3PL operations, with the aim to then roll out globally.
AmerisourceBergen, a leading pharmaceutical solutions organisation announced its intent to change its name to 'Cencora' to better reflect its bold vision and
purpose-driven approach to creating healthier futures.
Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen said: "Over time, we have established ourselves as a trusted industry partner
that prioritizes innovation, advocates for patient access and advances strategic partnerships across the global pharmaceutical supply chain. To further bolster our
position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental
to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care."
AmerisourceBergen intends to begin operating as Cencora in the second half of calendar year 2023. The change to Cencora is aligned with the organisation's growth
strategy and continued emphasis on innovation. AmerisourceBergen has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and
providers across the global healthcare supply chain.
DE Group, one of the UK's leading independent pharmaceutical wholesalers, has gone into administration.
Pharmacy Business has learnt that the group was put into administration on Monday (May 9), putting hundreds of jobs at risk and stoking fears of a "sudden shock"
to pharmaceutical supply chain.
A community pharmacy contractor who has done business with the wholesaler for over 20 years told Pharmacy Business: "I fear for the worst. I don't think there will
be enough supply of medicines to cope up with a surge at such a short notice."
Bharat Shah, founder and CEO of Sigma Pharmaceuticals, another leading short-line wholesaler, said the news will send shock-waves and have "a massive impact on the
market" because DE Group enjoyed a "substantial coverage and market share" in the independent pharmacy sector.
"It won't be easy for anyone to take on the extra volume as it could jeopardise their own business," he said, adding that Sigma was actively looking into expanding its own operations in the foreseeable future.
Northern Ireland will see changes in the regulatory landscape following the issuance of the Windsor Framework on 27th Feb 2023 and the corresponding EU
Commission proposal. An agreement, in principle, has been reached by the UK and EU.
The new path forward of the Windsor Framework marks a turning point in how both the UK and the EU will work together collaboratively and constructively to ensure
that the same medicines are available in Northern Ireland at the same time as they are in the rest of the United Kingdom.
Whilst this is a successful result for Northern Ireland patients, this is major change for companies that have made specific provisions in their supply chains for
Northern Ireland. The supply chains of companies where provisions and changes were made such as introduction of GB specific pack may be impacted as a result.
However, the burden on the UK Pharma supply chain will be eased.
Prime Minister Rishi Sunak walks with European Commission chief Ursula von der Leyen in Windsor on February 27, 2023
Pharma companies will need to carefully consider making changes within their processes and supply chains pending the issuance of clear guidance from the MHRA on
the regulation changes resulting from the Windsor Agreement and the corresponding EU Commission proposed regulatory changes associated with medicinal products
within the Northern Ireland market.
Smooth access to the EU market for Northern Ireland pharmaceutical and medical technology firms has been safeguarded within the constraints of the agreement. The
pragmatic dual-regulatory system protects business, patients and healthcare services, and reflects that it is an essential state function to maintain and oversee
the supply of medicines within the whole United Kingdom.
AAH Pharmaceuticals Ltd (AAH) has exceeded the milestone of delivering over 70 million COVID-19 vaccination doses across England, since it was awarded a
contract in December 2020.
In addition, AAH has delivered over 100 million ancillary items to more than 3,000 healthcare providers.
David Bound, chief executive officer of AAH, said: "This is a huge milestone for AAH as we work tirelessly to support our communities. It's also a ringing
endorsement of our delivery drivers, warehouse operatives, and specialist logistics teams and the determination, dedication, and passion they continue to show
throughout this extraordinary period."
The vaccination programme was also recognized by the Supply Chain Excellence Awards.
Chris Emmott, senior project lead - Supply Chain, commented: "I'm incredibly proud that AAH was chosen for this job, particularly as we had the skills, the
experience, and a great team to help facilitate the needs of the country. To get ready for a project like this, everybody's worked very long hours, they've
worked weekends to get everything ready.
AAH Pharmaceuticals on Tuesday (November 15) announced the promotion of its commercial director David Bound to chief executive officer of the company.
In his 10 years in the company, Mr Bound has helped to drive growth across the AAH business, implementing new digital channels for customers, and developing
strategic partnerships with pharmaceutical manufacturers - drawing on from his vast experience in the healthcare industry, as well as in supply chain, operations,
and trading.
Commenting on his promotion, he said: "I'm delighted to be taking on this role at such a critical time for healthcare. There are many challenges affecting the
industry right now - from inflationary pressures to workforce issues - and I'm looking forward to tackling them head-on alongside my excellent team."
Community Pharmacy England (CPE) to host a Parliamentary drop-in event in July to brief MPs and Peers about the ongoing medicines supply chain issues that
are negatively affecting pharmacies and their patients across the country.
CPE's Pressures Survey earlier this year highlighted the extent of both the operational and financial impacts of medicines supply issues on pharmacy businesses,
therefore it has continued to hear from both pharmacy owners and others about the problems.
The event aims to ensure that MPs understand the problems and their impact on pharmacies.
Peter Dowd MP is hosting the event, joined by representatives from Community Pharmacy England, the Nuffield Trust, patient groups and more.
The event will also be another opportunity to talk to MPs from across the political spectrum about the very serious situation that community pharmacies still find
themselves in and the need for further investment in the sector.
Janet Morrison OBE, Chief executive of Community Pharmacy England said: "The results of our Pressures Survey earlier this year showed just how much supply issues
are continuing to negatively impact pharmacy businesses and all those who work in them. The survey found that almost all pharmacy owners (97%) are facing
significant increases in wholesaler and medicine supply issues, with 71% saying this was leading to delays in prescriptions being issued.
British Pharma giant, GSK is planning to invest more than £200 million (about $253 million) into the United Kingdom over the next two years to strengthen
its manufacturing network.
The money will be used to improve the pharmaceutical group's UK sites, including construction of new facilities and assembly lines, The Daily Mail first reported
on Sunday.
GSK has already earmarked £67 million to upgrade its manufacturing site in Montrose, Scotland, where a new production facility is being constructed. The upgrade
is expected to help boost its production of active pharmaceutical ingredients (API) for the future supply of medicines.
Regis Simard, head of global supply chain, told the publication that their six UK manufacturing sites, including Montrose, are an important part of their global
manufacturing network.
From over-the-counter flu tablets to crucial antibiotics and antidepressants, medicines are running scarce in UK pharmacies this year, causing concerns among
patients, the government, and the wider pharma industry.
Drug shortages have accelerated over the past year due to a clutch of problems including the after-effects of the pandemic on supply chains, the war in Ukraine,
and soaring input costs weighing on manufacturers. More recently, a sudden spike in respiratory infections - another by-product of Covid-19 that neither pharma
companies nor the government were able to predict - has deepened the crisis, with 70 commonly taken drugs out of stock in Britain as of February.
The problem is not unique to the UK. In a recent survey of groups representing pharmacies in 29 European countries, three quarters said shortages were worse this
winter than a year ago, with a quarter reporting more than 600 drugs in short supply. The US is also facing significant shortages of popular prescription drugs like
amoxicillin and Adderall, an ADHD medication.
To some extent, the current disruption is laying bare wider challenges facing the industry for several years that were only exacerbated by the pandemic.
The over-reliance on foreign suppliers for most active pharmaceutical ingredients (APIs) is one of them. This model has left companies more susceptible to supply
shocks, which have in turn increased in frequency and severity due to pandemic lockdowns, the war in Ukraine and other issues such as the shortage of shipping
containers.
Pharma's long and opaque supply chains, alongside regulatory complexities, also mean it is taking longer for drugmakers to reconfigure manufacturing and distribution
in times of additional need.
The European Commission launched an initiative to deal with the ongoing supply crisis on Tuesday (24 October).
The following announcement comes after the shortage of key antibiotics last winter identified by the European Health Emergency Preparedness and Response
Authority (HERA) and the European Medicines Agency (EMA).
The "European Voluntary Solidarity Mechanism" is a proposed short-term measure that involves a Member State's need for a given medicine to other Member States
to redistribute medicines from their available stock.
Additionally, the Commission intends to cooperate with member states to improve components of pharmaceutical reform with an aim to strengthen supply security.
They are setting up a few actions apart from the launch, a list of critical medicines to analyse the supply chain by early 2024; regulatory flexibilities;
strengthening security of supply; and availability of antibiotics and treatments for respiratory viruses by next winter.
he Healthcare Distribution Association (HDA) and the Pharmaceutical Services Negotiation Committee (PSNC) have urged the NHS England and the Department of
Health and Social Care (DHSC) to issue urgent communications requesting that all those involved in medicines supply do not hoard, stockpile or over-prescribe Strep
A antibiotics.
In a statement HDA said that the sudden spike in demand for antibiotics used for the treatment of Strep A has meant that there is not enough of these medicines in
the supply chain currently to meet this increased demand. As a result, wholesalers are working extremely hard with manufacturers to increase the supply of antibiotics.
It added: "As regards pricing, the prices charged to pharmacies by HDA wholesale distributors will directly reflect the increase in prices wholesalers are having
to pay for these medicines from manufacturers at the moment, in order to be able to continue supplying these medicines to pharmacies. This will be the case until
supply and demand are more in sync."
The General Pharmaceutical Council (GPhC) has urged health and care professionals to meet relevant regulatory standards amidst the shortage of GLP-1 receptor
agonists (GLP-1 RAs).
The council said: "We are concerned to hear that people with Type 2 diabetes are experiencing problems accessing GLP-1 receptor agonists (GLP-1 RAs). We know that
these are being widely prescribed for weight loss purposes and in some cases prescribed off-label."
"We recognise the adverse impact that shortages and supply chain issues can have on patients, the public and wider health and care teams.
The Council understands that health and care professionals are using their professional judgement and making decisions in challenging situations, balancing a range
of factors such as individual patient needs, wider public health and pressures and limitations on available resources such as medicines shortages or other supply
chain issues.
The International Pharmaceutical Federation (FIP) has offered a new resource to help countries self-assess readiness of their regulations to enable
pharmacist-delivered vaccination services and, where needed, to implement such regulations.
Developed by FIP's Regulators Advisory Group, it covers broad pharmacist-led roles related to vaccination from supply chain management to administration and
prescribing.
"This new resource from FIP is based on the experiences of professional regulators in countries where pharmacy-led vaccination has been successfully introduced
and regulated. With it, we aim to support regulators, policymakers and national organisations in developing strategies or enabling regulatory frameworks in
countries where the pharmacy workforce has a limited role in vaccination strategies so that it can contribute further to the global imperative of improving
immunisation coverage," said Brett Simmonds, group chair.
The "Pharmacy-led vaccination services: Regulatory self-assessment and implementation tool" aims to help identify strengths and areas for improvement in order to
inform vaccination policy and planning efforts.
The Equality Act (which replaced the Disability Discrimination Act in 2010) is often cited as a reason for supplying medicines in a compliance aid. This is a complex piece of legislation, but, in essence, provides a statutory duty on businesses to make "reasonable adjustments" in relation to the service that they provide to take into account any relevant disability of a service-users.
This statutory obligation might include the provision of a compliance aid where a patient would be at a "substantial disadvantage" without. However, the need to provide medicines in a compliance aid under the Equality Act needs careful consideration and is a balancing exercise.
The NHS Terms of Service for community pharmacies in England state that medicines should be provided in original packs save in certain circumstances, which include because of patient needs.
Alliance Healthcare UK has won a 'special achievement' award for its work during the Covid-19 pandemic at the Logistics UK Awards 2021.
The pharmaceutical wholesaler and it's subsidiary, Alloga UK - a specialist provider of supply chain solutions for healthcare manufacturers - received the 'Special Recognition Award for Outstanding Response to Covid' at an event held in central London on Thursday, December 9, 2021 - beating off stiff competition from a number of high profile challengers.
Alliance Healthcare's new managing director Marie Evans said: "I am delighted that our business and team of 6,000 colleagues have been recognised at this level for our contribution to the fight against Covid-19. Our main aim over this unprecedented period is to support the NHS, pharmacy and all UK patients, and this award is true recognition for all of that hard work and dedication."
The special award category was open to an individual or organization that demonstrated an outstanding response to the pandemic in 2020 within the logistics sector and included seven other nominees including the likes of National Highways, Hermes UK and Yodel.
Essential Pharma, an international speciality pharma group, has procured an establishment and manufacturing licences in Switzerland and Malta.
Following a successful inspection by Swissmedic, the company has been granted an establishment licence in Switzerland, which will allow the company to significantly
enhance its supply chain efficiency for a wide range of important medicinal products. It will apply to transactions for both finished and unfinished pharmaceuticals,
allowing importing, exporting, wholesaling and trading abroad.
Essential Pharma has also received a manufacturing and importation authorisation (MIA) in Malta, following a successful Good Manufacturing Practice (GMP) inspection
by the Malta Medicines Authority.
The MIA will allow the company to import medicinal products into the European Union where manufacturing has taken place in a third country. This will allow greater
flexibility in how the business manages the flow of medicines across its territories.
These approvals strengthen the company's geographical expansion, improve its operational efficiencies, and enhance its offering as a global business partner. They
will also provide new strategic opportunities for the company and will play a fundamental role in driving value creation through functional improvements to scale
and productivity.